Skip to main content

Advertisement

Table 4 5-Azacytidine (5-Aza) as maintenance therapy after haematopoietic transplantation (HSCT)

From: Epigenetic approaches in stem cell transplantation

Author n Agent Disease Duration Outcome Ref.
de Lima 2007 40 5-Aza AML/MDS up to 4 cycles at 28 days 11× relapse (de Lima et al. 2007)
Jabbour 2009 8 5-Aza (+3× HSCT) 7× AML, 1× ALL median 8 cycles á 28 days (up to 22 cycles) 3 x relapse, 7× alive (Jabbour et al. 2009)
  1. AML acute myeloid leukaemia, MDS myelodysplasia, ALL acute lymphoblastic leukaemia